Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ErythroMer is a first-in-class, dried, bio-inspired artificial red blood cell designed as a universal blood substitute for the treatment of life-threatening blood loss when stored red blood cells are unavailable, undesirable, or in short supply. Developed by KaloCyte, it consists of purified human hemoglobin encapsulated within a soft lipid nanoparticle shell that mimics native erythrocytes. The design incorporates proprietary lipids and 2,3-diphosphoglycerate (2,3-DPG) to regulate hemoglobin’s oxygen affinity in response to pH changes—emulating natural oxygen capture and release mechanisms of real RBCs. ErythroMer can be freeze-dried for long-term storage at ambient temperature and reconstituted with saline for rapid use in emergency settings such as trauma care or battlefield medicine. It is intended to be universally compatible across all blood types due to the absence of surface antigens found on natural RBCs. Preclinical studies have demonstrated effective oxygen delivery and safety in animal models; human trials are planned but not yet initiated[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ErythroMer.